Latest Amorfix Life Sciences Ltd. Stories

2014-01-22 08:29:18

TSX: AMF TORONTO, Jan. 22, 2014 /CNW/ - Amorfix Life Sciences Ltd. announced today that the Company has signed an agreement with a major global pharmaceutical company to use the human Alzheimer's disease diagnostic assay in phase 1 clinical studies. Amorfix has granted its collaborator access to its proprietary EP-AD assay technology and the Company will complete assay optimization and validation prior to using the assay as part of a clinical trial to investigate the effects...

2009-12-08 08:00:00

WATERTOWN, Mass., Dec. 8 /PRNewswire/ -- EnVivo Pharmaceuticals today reported the successful reduction in the levels of aggregated Abeta or Beta-Amyloid in an aged transgenic model (Tg2576) of Alzheimer's disease with its lead gamma-secretase modulator (GSM) EVP-0962. The aggregated Abeta, containing predominately oligomeric and larger Abeta fibrillar species, is considered to be the toxic entity in Alzheimer's disease. The reduction of these aggregates further supports the disease...

Word of the Day
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'